Rosacea treatment is a marathon — not a sprint — and there’s a need for increased emphasis on a patient-centric approach to ...
The licensing deal could set the US drugmaker to vie with Eli Lilly & Co. and Novo Nordisk A/S, the current leaders in a ...
AbbVie is jumping into the burgeoning obesity field, striking a license agreement with Gubra that is potentially worth more than $2 billion to the Danish drug-discovery and contract-research-services ...
Eli Lilly and Company LLY announced that the European Medicines Agency's Committee for Medicinal Products for Human Use ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback